Authors
Latest:
Thierry André, MD, on Interim Results from the Phase III Keynote-177 StudyThe findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Latest:
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic TumorsThe expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy.
Latest:
John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 StudyThe expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.
Latest:
Key Advances Across Kidney Cancer Research and Management at KCRS 2025Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Latest:
Sacituzumab Govitecan Yields Improved Survival Regardless of Trop-2 Levels for HR+/HER2– Breast CancerImprovements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.
Latest:
Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 TrialThe expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.
Latest:
JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple MyelomaThe 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.
Latest:
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian CancerApproximately half of the patients who received raludotatug deruxtecan in the phase 2/3 REJOICE-Ovarian01 trial achieved an objective response.
Latest:
Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate CancerPrevious results from the study found improvement in the primary end point of PSA-PFS with apalutamide in recurrent prostate cancer.
Latest:
ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell LymphomasNirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
The Role of Autologous Stem Cell Transplantation in AmyloidosisAutologous stem cell transplantation has been an essential part of the treatment armamentarium in light chain amyloidosis for several decades. This review provides a comprehensive assessment of eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Martin Reck, MD, PhD, Discusses NSCLC Data of Interest From 2021 ASCOReck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.
Latest:
Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Advanced Penile Cancer Presenting With Renal Failure“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
Latest:
Highlighting Breast Cancer Advances at IBC EastLeading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Latest:
PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment LandscapePanelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.
Latest:
Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic MalignanciesCancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma TreatmentZenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
Latest:
Phyllis Morgan on Health Disparities in Patients At Risk for Developing Colorectal CancerPhyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.
Latest:
Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLLTreatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.
Latest:
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited SettingA recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.
